ltLNP3AKO

N/A

Report date: 2025/09/05 16:16:18

Base Information

Drug NameltLNP3AKO
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > LNP
Mechanisms of ActionATPase Family AAA Domain Containing 3A modulators
TargetsATPase Family AAA Domain Containing 3A
Therapy Area/IndicationsNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEmory University
China Registration ClassN/A

Develop Information

Active CompaniesEmory University
Inactive CompaniesN/A
Active IndicationsNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A